ArtNr |
HY-130149-100mg |
Hersteller |
MedChem Express
|
CAS-Nr. |
2326521-71-3 |
Menge |
100 mg |
Quantity options |
100 mg
10 mM/1 mL
10 mg
1 mg
25 mg
500 mg
50 mg
5 mg
|
Kategorie |
|
Typ |
Inhibitors |
Specific against |
other |
Purity |
99.93 |
Formula |
C32H35ClFN7O2 |
Citations |
[1]Christensen JG, et al. The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients. Cancer Discov. 2019 Oct 28. pii: CD-19-1167. [2]Kyriakos P. Papadopoulos, et al. A phase I/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with KRAS G12C mutation. Journal of Clinical Oncology 2019 37:15_suppl, TPS3161-TPS3161. [3]Fell JB, Fischer JP, Baer BR, et al. Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer. J Med Chem. 2020;63(13):6679-6693. [4]Awad MM, Liu S, Rybkin II, et al. Acquired Resistance to KRASG12C Inhibition in Cancer. N Engl J Med. 2021;384(25):2382-2393. |
Smiles |
N#CC[C@@H]1N(C(C(F)=C)=O)CCN(C2=C3C(CN(C4=C5C(Cl)=CC=CC5=CC=C4)CC3)=NC(OC[C@H]6N(C)CCC6)=N2)C1 |
ECLASS 10.1 |
32160490 |
ECLASS 11.0 |
32160490 |
UNSPSC |
12000000 |
Alias |
MRTX849 |
Similar products |
2326521-71-3 |
Versandbedingung |
Raumtemperatur |
Lieferbar |
|
Manufacturer - Type |
Reference compound |
Manufacturer - Applications |
Cancer-Kinase/protease |
Manufacturer - Targets |
Ras |
Shipping Temperature |
Room Temperature |
Storage Conditions |
-20°C, 3 years; 4°C, 2 years (Powder) |
Molecular Weight |
604.12 |
Product Description |
Adagrasib (MRTX849) is a potent, orally-available, and mutation-selective covalent inhibitor of KRAS G12C with potential antineoplastic activity. Adagrasib covalently binds to KRAS G12C at the cysteine at residue 12, locks the protein in its inactive GDP-bound conformation, and inhibits KRAS-dependent signal transduction[1][2]. |
Manufacturer - Research Area |
Cancer |
Solubility |
DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C) |
Manufacturer - Pathway |
GPCR/G Protein; MAPK/ERK Pathway |
Isoform |
K-Ras |
Clinical information |
Launched |
Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.
Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.